| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/15/2015 | US20150018320 Hormone Containing Emulsion Comprising Krill Phospholipids |
| 01/15/2015 | US20150018319 Treatment of skin disease |
| 01/15/2015 | US20150018315 Novel tetra- and pentasubstituted benzimidazolium compounds |
| 01/15/2015 | US20150018314 Novel benzimidazolium compounds |
| 01/15/2015 | US20150018313 Novel 5-substituted benzimidazolium compounds |
| 01/15/2015 | US20150018312 Nitrogen containing compounds and their use |
| 01/15/2015 | US20150018308 Preparation of Triple Responsive Nanogel System and its Application |
| 01/15/2015 | US20150018305 Sirtuin inducer, tissue repairing agent, hepatocyte growth factor inducer, tissue homeostasis maintenance agent, and tlr4 agonist, having hyaluronic acid fragment as active ingredient |
| 01/15/2015 | US20150018304 Diet product comprising alginate |
| 01/15/2015 | US20150018303 Compositions of hyaluronan with high elasticity and uses thereof |
| 01/15/2015 | US20150018302 Compositions comprising ndga derivatives and sorafenib and their use in treatment of cancer |
| 01/15/2015 | US20150018301 LRRK-2-Mediated Neuronal Toxicity |
| 01/15/2015 | US20150018300 Compounds |
| 01/15/2015 | US20150018299 Treatment of liver conditions |
| 01/15/2015 | US20150018298 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| 01/15/2015 | US20150018297 Composition for preventing or treating degenerative brain diseases including compound downregulating expression of bace1 proteins |
| 01/15/2015 | US20150018296 Therapeutic methods and compositions utilizing cyclohexenone compounds |
| 01/15/2015 | US20150018295 Method for the preparation of triglycerides of medium-chain length fatty acids |
| 01/15/2015 | US20150018294 Modulators of tousled kinase in cellular processes |
| 01/15/2015 | US20150018293 Animal treatments |
| 01/15/2015 | US20150018290 Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders |
| 01/15/2015 | US20150018277 Combination of a Leucine Source and an Omega-3 Unsaturated Fatty Acid Source for Use in the Treatment of Hypercalcaemia |
| 01/15/2015 | US20150018276 Method of treatment of cancer using guanosine 3', 5' cyclic monophosphate (cyclic gmp) |
| 01/15/2015 | US20150017699 Internally functionalized graphene substrates |
| 01/15/2015 | US20150017673 Compositions and methods for drug-sensitization or inhibition of a cancer cell |
| 01/15/2015 | US20150017651 Personalized medicine for the prediction of therapy targeting the hedgehog pathway |
| 01/15/2015 | US20150017267 Treatment of Inflammatory Disorders in Non-Human Mammals |
| 01/15/2015 | US20150017266 Compositions and Methods for Relieving Symptoms of Rheumatoid Arthritis and Related Illnesses |
| 01/15/2015 | US20150017264 Procaspase 3 activation by combination therapy |
| 01/15/2015 | US20150017263 Fn14 antagonists and therapeutic uses thereof |
| 01/15/2015 | US20150017262 Inhibition of dynamin related protein 1 to promote cell death |
| 01/15/2015 | US20150017260 Compositions of nutrition supplementation for nutritional deficiencies and method of use thereof |
| 01/15/2015 | US20150017251 Microparticles for use in immunogenic compositions |
| 01/15/2015 | US20150017250 Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| 01/15/2015 | US20150017249 Sustained-release formulations of topiramate |
| 01/15/2015 | US20150017248 Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation |
| 01/15/2015 | US20150017247 Compositions for pulmonary delivery of long-acting b2 adrenergic receptor agonists and associated methods and systems |
| 01/15/2015 | US20150017245 Methods of treating cancers with therapeutic nanoparticles |
| 01/15/2015 | US20150017244 Dry powder formulation of azole derivative for inhalation |
| 01/15/2015 | US20150017243 Compositions and methods for enhancing brain function |
| 01/15/2015 | US20150017242 Bilayer Tablet of Dronedarone |
| 01/15/2015 | US20150017241 Oral formulations of deferasirox |
| 01/15/2015 | US20150017240 Pharmaceutical compositions comprising a ph-dependent component and ph-raising agent |
| 01/15/2015 | US20150017239 Method for treating intestinal diseases presenting at least one inflammatory component |
| 01/15/2015 | US20150017237 Dosage form comprising lopinavir and ritonavir |
| 01/15/2015 | US20150017236 Pharmaceutical compositions of thyroid hormone |
| 01/15/2015 | US20150017234 Increased effectiveness of allylamine drug compounds for topical treatment of fungal infections of the skin and skin appendages |
| 01/15/2015 | US20150017233 Arginine-based lipids for delivery of therapeutics |
| 01/15/2015 | US20150017231 Polyamine transport selective therapeutic agents with enhanced stability |
| 01/15/2015 | US20150017228 Method and system for synthesizing nanocarrier based long acting drug delivery system for morphine |
| 01/15/2015 | US20150017227 Methods and Compositions for Treating Skin Diseases and Conditions |
| 01/15/2015 | US20150017226 Tolterodine-containing adhesive patch |
| 01/15/2015 | US20150017223 Edible coating composition and uses thereof |
| 01/15/2015 | US20150017216 Compositions and methods for target delivering a bioactive agent to aquatic organisms |
| 01/15/2015 | US20150017213 Ocular Composition and Kits Thereof |
| 01/15/2015 | US20150017203 Combination product for treating excess weight and/or for improving the figure |
| 01/15/2015 | US20150017189 Methods of making and using nanostructures |
| 01/15/2015 | US20150017185 Method to improve the immune function of t cells |
| 01/15/2015 | US20150017182 Methods for treating nasal polyposis by administering an il-4r antagonist |
| 01/15/2015 | US20150017176 Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
| 01/15/2015 | US20150017175 Methods of administering anti-tnfalpha antibodies |
| 01/15/2015 | US20150017174 Composition |
| 01/15/2015 | US20150017164 COMBINATION OF BLyS AND/OR APRIL INHIBITION AND IMMUNOSUPPRESSANTS FOR TREATMENT OF AUTOIMMUNE DISEASE |
| 01/15/2015 | US20150017163 Methods for Treating or Preventing Ophthalmological Conditions |
| 01/15/2015 | US20150017160 Combinations and uses thereof |
| 01/15/2015 | US20150017158 Tetrahydrofolates in combination with egfr-inhibitors |
| 01/15/2015 | US20150017157 Methods for treating acne |
| 01/15/2015 | US20150017156 Esx-mediated transcription modulators and related methods |
| 01/15/2015 | US20150017151 Pharmaceutical formulations of xanthine or xanthine derivatives, and their use |
| 01/15/2015 | US20150017147 Methods and products to provide oral nutritional care to subjects with dementia |
| 01/15/2015 | US20150017144 Compositions for the treatment of clostridium difficile associated disease, methods of their use and methods of making the same |
| 01/15/2015 | US20150017143 Composition comprising specific lactobacillus helveticus strains and reducing food and/or respiratory allergy symptoms |
| 01/15/2015 | US20150017137 Drug resistant immunotherapy for treatment of a cancer |
| 01/15/2015 | US20150017128 Strains of lactic acid bacteria and/or bifidobacteria inhibiting/reducing the growth of different biotypes of e. coli and different biotypes of clostridia |
| 01/15/2015 | US20150017126 Poxviral oncolytic vectors |
| 01/15/2015 | US20150017124 Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
| 01/15/2015 | US20150017117 Composition for In Vivo Vessel Repair |
| 01/15/2015 | US20150017115 Polymers having therapeutically active agents conjugated thereto, processes of preparing same and uses thereof |
| 01/15/2015 | US20150017104 Compositions, methods & systems for respiratory delivery of two or more active agents |
| 01/15/2015 | US20150017103 Compositions with Modulating Agents |
| 01/15/2015 | US20150017099 Diagnosis and treatment for respiratory tract diseases |
| 01/15/2015 | US20150017098 Carrier that targets fucosylated molecule-producing cells |
| 01/15/2015 | US20150017091 Detection and treatment of metastatic disease |
| 01/15/2015 | US20150013695 Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same |
| 01/14/2015 | EP2824184A1 micro-RNA INHIBITOR |
| 01/14/2015 | EP2824109A1 Nucleoside phosphoramidate prodrugs |
| 01/14/2015 | EP2824108A1 Tetracyclic anthraquinone derivatives |
| 01/14/2015 | EP2824106A1 Tricyclic compound |
| 01/14/2015 | EP2824105A1 Indolopyridines as Eg5 kinesin modulators |
| 01/14/2015 | EP2824103A1 An improved process for the preparation of Rupatadine Fumarate |
| 01/14/2015 | EP2824102A1 Androgen receptor modulators and uses thereof |
| 01/14/2015 | EP2824100A1 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| 01/14/2015 | EP2824099A1 Novel triazine derivative |
| 01/14/2015 | EP2824097A1 Prolinamide derivative as thrombin inhibitor, preparation method and application thereof |
| 01/14/2015 | EP2823826A2 Inhibitors of carbonic anhydrase IX |
| 01/14/2015 | EP2823825A1 Pharmaceutical composition for treating cancer |
| 01/14/2015 | EP2823821A1 Antibody specifically binding to digoxigenin |
| 01/14/2015 | EP2823820A1 Liposomes comprising an aminoglycoside for the treatment of pulmonary infections |
| 01/14/2015 | EP2823819A2 Pharmaceutical composition containing oleanolic acid acetate as an active ingredient for preventing or treating tlr- or il-6-mediated diseases |
| 01/14/2015 | EP2823818A1 Use of rupatadine in the manufacture of pharmaceutical composition for treating chronic obstructive pulmonary disease |